Comparative Pharmacology
Head-to-head clinical analysis: DOPTELET SPRINKLE versus ELTROMBOPAG OLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOPTELET SPRINKLE versus ELTROMBOPAG OLAMINE.
DOPTELET SPRINKLE vs ELTROMBOPAG OLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DOPTELET (avatrombopag) is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor on megakaryocytes and megakaryocyte precursor cells, leading to differentiation, proliferation, and increased platelet production.
Thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor (c-Mpl), leading to increased proliferation and differentiation of megakaryocytes and subsequent platelet production.
10 mg (5 capsules) orally once daily for 5 consecutive days. Two to 4 hours before planned procedure, total dose should be taken 5 days prior to the procedure.
50 mg orally once daily; for patients of East Asian ancestry with ITP, start at 25 mg orally once daily. Dose adjustments based on platelet counts: increase up to 75 mg daily or decrease to 25 mg daily as needed.
None Documented
None Documented
Terminal half-life approximately 31-35 hours; supports once-daily dosing
Terminal elimination half-life is approximately 21–32 hours (mean ~29 hours) in healthy subjects. At steady state, clinically relevant due to once-daily dosing with delayed platelet response.
Fecal (approx. 59%), renal (approx. 31%) as unchanged drug and metabolites
Primarily fecal (59%) and renal (31%), with unchanged drug representing <1% in urine and ~20% in feces; biliary elimination accounts for most of the fecal route.
Category C
Category C
Thrombopoietin Receptor Agonist
Thrombopoietin Receptor Agonist